Search Within

Clinical Pharmacy Specialists

Formats
  1. Journal Article (132)
  2. Meeting Abstract (130)
  3. Research Letter (10)
  4. Review (6)
  5. Book Section (5)
  6. Guidelines (5)
  7. Editorial (2)
  8. Miscellaneous (2)
Groups
  1. Department of Medicine (216)
  2. Center for Hematologic Malignancies (140)
  3. Hematologic Malignancies, Division of (136)
  4. Survivorship Research (103)
  5. Bone Marrow Transplant (86)
  6. CTCR Scholars (84)

More Groups

People
  1. Sergio Giralt (63)
  2. Andrew Lin (51)
  3. Dazhi Liu (45)
  4. Gunjan Shah (44)
  5. Michael Scordo (40)
  6. Susan Seo (35)

More People

Years
  1. 2025 (13)
  2. 2024 (48)
  3. 2023 (28)
  4. 2022 (33)
  5. 2021 (13)
  6. 2020 (14)

More Years

Publications
  1. Blood (42)
  2. Biology of Blood and Marrow Transplantation (27)
  3. Journal of Clinical Oncology (21)
  4. Pediatric Blood and Cancer (13)
  5. Blood Advances (12)
  6. Clinical Lymphoma, Myeloma and Leukemia (11)

More Publications

Publishers
  1. Elsevier Inc. (59)
  2. American Society of Hematology (54)
  3. American Society of Clinical Oncology (25)
  4. Oxford University Press (17)
  5. Springer (13)
  6. Wiley Periodicals, Inc (13)

More Publishers

Results (292)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Infectious complications during treatment with commercial CAR T-cell therapy and bispecific antibodies for relapsed/refractory multiple myeloma
    Meeting Abstract

    Jurgens, E. M.; Shekarkhand, T.; Farzana, T.; Rueda, C.; Nemirovsky, D.; Derkach, A.; Firestone, R. S.; Nishimura, N.; Miller, K.; Costa, B. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Frailty and outcomes after bispecific T-cell engager therapy for patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Adegbite, B. O.; Tan, C. R.; Shekarkhand, T.; Firestone, R. S.; Jurgens, E. M.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; Rajeeve, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Patients with AML and an IDH2-R172 mutation exhibit a unique response to intensive induction chemotherapy, suggesting futility of mid-cycle bone marrow biopsy and caution when considering re-induction
    Meeting Abstract

    Yisraeli Salman, M.; Terry, A. R.; Derkach, A.; Nemirovsky, D.; Chin, K. K.; Valtis, Y. K.; Boussi, L.; Spivey, T.; Xiao, W.; Famulare, C.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • How a self-assessment mobile app for cancer treatment facilities became a tool for successful collaborations with Ministries of Health and NGOs
    Meeting Abstract

    Swindell, J.; Nwokwu, U.; Dr, K. A.; Koranteng, L.; O'Brien, D. M.
    International Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Phase II study of pharmacokinetic model-based ATG dosing to improve survival through enhanced immune reconstitution in patients undergoing ex vivo CD34-selected allogeneic HCT (PRAISE-IR)
    Meeting Abstract

    Scordo, M.; Perales, M. A.; Mauguen, A.; Lin, A.; Kunvarjee, B.; Bieler, J.; Nguyen, L. K.; Paes Pena, M.; Cho, C.; Gyurkocza, B.; more...
    Bone Marrow Transplantation (2024)

    Fulltext@MSK | Save
  • Advancing global health equity in oncology clinical trial access
    Editorial

    Bloomberg New Economy International Cancer Coalition; McKinsey Cancer Center; Cure4Cancer
    Cancer Discovery (2024)

    Fulltext@MSK | Save
  • Defining the rates of cytokine release syndrome associated with Talquetamab step-up doses
    Meeting Abstract

    Hamadeh, I.; Shekarkhand, T.; Rueda, C.; Firestone, R.; Wang, A.; Korde, N.; Hultcrantz, M.; Lesokhin, A.; Mailankody, S.; Hassoun, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Impact of granulocyte colony-stimulating factor exposure on cytokine release syndrome during bispecific antibody initiation in relapsed/refractory multiple myeloma
    Meeting Abstract

    Wang, A.; Shekarkhand, T.; Derkach, A.; Nemirovsky, D.; Tan, C.; Hamadeh, I.; Firestone, R.; Jurgens, E.; Miller, K.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • CMV reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma
    Meeting Abstract

    Jurgens, E.; Shekarkhand, T.; Rueda, C.; Nemirovsky, D.; Derkach, A.; Firestone, R.; Miller, K.; Costa, B.; Rajeeve, S.; Lesokhin, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B.; Rajeeve, S.; Jurgens, E.; Nishimura, N.; Farzana, T.; Firestone, R.; Miller, K.; Lesokhin, A.; Shah, G.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save